{"id":"W4415817417","doi":"10.1007/s11523-025-01182-0","title":"Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Loxo Oncology; Eli Lilly Japan; Chugai Pharmaceutical; Genentech; Grifols; Casen Recordati; Japanese Society of Medical Oncology; Pfizer Japan; Sociedad Española de Oncología Médica; Shionogi; Astellas Pharma; Eisai; Seagen; Lunit; Johnson and Johnson; Les Laboratories Pierre Fabre; Verily Life Sciences; BeiGene; Mirati Therapeutics; Ipsen; Five Prime Therapeutics; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Puma Biotechnology; Regeneron Pharmaceuticals; Yuhan; Daiichi Sankyo Europe; LEO Pharma; Gilead Sciences; Sanofi; Pfizer; Innovent Biologics; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; AstraZeneca; Amgen; Mesothelioma Applied Research Foundation","keywords":"Lung cancer; Exon; Phases of clinical research; Epidermal growth factor receptor; Cell; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01310331,0.0007897274,0.001625068,0.0002900358,0.0002762469,0.0008789733,0.0006047172,0.0009412437,0.001903917],"category_scores_gemma":[0.007570739,0.0002797566,0.003340768,0.0004487197,0.0005954093,0.0005603322,0.0006161868,0.001710423,0.0001544237],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008744427,"about_ca_system_score_gemma":0.001183677,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004685129,"about_ca_topic_score_gemma":0.001119353,"domain_scores_codex":[0.9927366,0.005521629,0.0004709579,0.0004193337,0.0005731572,0.0002783715],"domain_scores_gemma":[0.9906688,0.004629773,0.002851485,0.000990195,0.0003085016,0.0005512747],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.9480096,0.004376732,0.01458664,0.0005327909,0.003249886,0.00004210057,0.0001059379,0.0009867741,0.00317594,0.0001105703,0.0003562699,0.02446674],"study_design_scores_gemma":[0.3913178,0.4419967,0.1395235,0.0002117883,0.01149861,0.0002903849,0.0001392003,0.0025282,0.007659752,0.0007657119,0.003976411,0.00009199621],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939204,0.001772568,0.001091212,0.00007458615,0.0000636223,0.00158739,0.000618614,0.00002051786,0.0008510836],"genre_scores_gemma":[0.9945065,0.0006236518,0.0008721623,0.0001366061,0.00005749068,0.002046673,0.001200944,0.00001736505,0.0005384804],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01310331,"threshold_uncertainty_score":0.06929773,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01319791740802506,"score_gpt":0.3870075524723263,"score_spread":0.3738096350643012,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}